IMPROVING DATA FOR DECISION-MAKING

A TOOLKIT FOR CERVICAL CANCER PREVENTION AND CONTROL PROGRAMMES

World Health Organization
CDC Centers for Disease Control and Prevention
CDC Foundation Together our impact is greater
George W Bush Institute

IMPROVING DATA FOR DECISION-MAKING

A TOOLKIT FOR CERVICAL CANCER PREVENTION AND CONTROL PROGRAMMES

World Health Organization
CDC Centers for Disease Control and Prevention
CDC Foundation Together our impact is greater
George W. Bush Institute

Improving data for decision-making: a toolkit for cervical cancer prevention and control programmes

ISBN 978-92-4-151425-5

© **World Health Organization 2018**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation.
Improving data for decision-making: a toolkit for cervical cancer prevention and control programmes. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data.
CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing.
To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials.
If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers.
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The mark "CDC" is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise. The guiding information provided in this report does not necessarily represent the official position of CDC.

Design and layout by blossoming.it

Printed in Spain

CONTENTS

- Acknowledgements x
- Abbreviations and acronyms xi
- Glossary xii
- Introduction to the toolkit 1
  - Cervical cancer in low- and middle-income countries 1
  - Purpose of the toolkit 1
    - Improving data for decision-making 1
    - Global monitoring 1
  - How to use the toolkit 2
    - Toolkit scope 2
    - Toolkit structure and content 3
    - Section 1: Rapid situational assessment of data and data systems 3
    - Section 2: Population-based survey modules 4
    - Section 3: Patient and programme monitoring 4
    - Section 4: Facility-based surveys 5
    - Section 5: Prevention and control costing – analysis and planning module for screening and treatment 5

SECTION 1: RAPID SITUATIONAL ASSESSMENT OF DATA AND DATA SYSTEMS 7

- Introduction 8
- Data systems assessment process 9
  - Objectives and scope 9
  - Timeline 9
  - Sampling 9
  - The rapid assessment process team 9
  - Phase 1 of the assessment 10
    - Specific objectives 10
    - Data collection 10
    - Identifying key contacts 10
    - Identifying exemplar programmes 10
    - Stakeholder inbrief 11
  - Phase 2 of the assessment 11
    - Specific objectives 11
    - Data collection 11
    - Stakeholder debrief 11
  - Data analysis 11

- Data management and protection 12
- Post-assessment 12
    - Assessment report writing and dissemination 12
- Ethical considerations 12
- Adaptation of the approach 12

• Data systems assessment tools 12
- Landscape survey questionnaire 13
- In-depth discussion guide 13
- Phase 1 data collection: conducting the landscape survey 13
    - Administration of landscape survey questionnaire 14
    - Desk review 14
    - When data are not available 14
- Phase 1 data review and preliminary analyses 16
    - Reconciling conflicting responses 16
    - Preparing for phase 2 16
- Phase 2 data collection: in-depth investigation of data systems 16
    - Interviews 17
    - Direct observation 17
    - Desk review 17
- Phase 2 data analysis and development of recommendations 18
    - Ongoing review and analysis 18
    - Development of recommendations 18

• Implementation tools and materials 18
- Assessment roles and responsibilities checklists 20
    - Pre-assessment checklist 20
    - Phase 1 checklist 20
    - Phase 2 checklist 21
    - Post-assessment checklist 22
- Landscape survey questionnaire 23
    - Landscape domain 1: demographics and epidemiology 24
    - Landscape domain 2: governance, management and infrastructure 24
    - Landscape domain 3: policies, plans, strategies and clinical guidelines 25
    - Landscape domain 4: service availability and utilization 27
    - Landscape domain 5: human resources for health 29
    - Landscape domain 6: equipment, supplies and medicines 32
    - Landscape domain 7: laboratory 34
    - Landscape domain 8: financing, budget and costing 35
    - Landscape domain 9: health information systems overview 37
- In-depth discussion guide 38
    - Domain 1: demographics and epidemiology 40
    - Domain 2: governance, management and infrastructure 43

- Domain 3: policies, plans, strategies and clinical guidelines 44
- Domain 4: service availability and utilization 45
- Domain 5: human resources 48
- Domain 6: equipment, supplies and medicines 50
- Domain 7: laboratory 50
- Domain 8: financing, budget and costing 52
- Domain 9: health information systems overview 53

- Suggested list of documents for desk review 58
- Exemplar programme interview discussion guide 59

SECTION 2: POPULATION-BASED SURVEY MODULES 63

• Introduction 64
• Core module 65
• Core plus module 66
• Methodological considerations for the survey modules 68
- Sampling method 68
- Sample size estimation 68
- Influence of estimated screening prevalence on survey question selection 69
- Respondent age 69
- Special considerations for areas with high prevalence of HIV 69
- Addressing bias 69
- Validation 70
- Cognitive testing 70
- Ethical review and human subjects protections 70
- Recommendation regarding HPV testing in population-based surveys 71
• Implementation tools and materials 72
- Survey formats 72
- Core module 72
- Core plus module 73
- Reference sheets 75
- Introductory statement 76
- Core questions 77
- Core plus questions 82
- Image examples for use with introductory statements 90
- Example table shells 92
- Example 1 92
- Example 2 93
- Example 3 94
- Example 4 95

SECTION 3: PATIENT AND PROGRAMME MONITORING 97

- Introduction 98
- Roles and Responsibilities for M&E 99
- Indicators 100
  - Indicators at global, national, subnational, and facility levels 100
    - Global-level indicators 101
    - National-level indicators 101
    - Subnational-level indicators 101
    - Facility-level indicators 101
  - Prioritizing indicators 101
  - Indicator denominators 104
  - Indicator disaggregation 104
    - Age ranges 106
    - HIV status 106
    - Screening visit type 107
  - Standardizing terminology: screening test results 108
    - VIA results 108
    - Pap smear/cytology results 109
    - HPV test results 109
    - Standardized terminology and data quality 109
  - Standardizing terminology: referral, postponement, and loss to follow-up 110
  - Monitoring screening and treatment strategies: classifying procedure purpose 110
    - Visual assessment for treatment: an additional consideration for classifying procedure purpose 110
  - Special considerations for areas with high HIV prevalence 111
- Routine service delivery data collection, aggregation, and reporting 112
  - Client level data collection 112
    - Client screening and treatment forms 112
    - Client level data elements 113
  - Facility level data collation 113
    - Register 113

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25366